Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study

• Published in: Journal of asthma and allergy Vol. 15; pp. 395 - 405
• Main Authors: Numata, Takanori, Araya, Jun, Miyagawa, Hanae, Okuda, Keitaro, Takekoshi, Daisuke, Hashimoto, Mitsuo, Minagawa, Shunsuke, Ishikawa, Takeo, Hara, Hiromichi, Kuwano, Kazuyoshi
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 30.04.2022; Dove; Dove Medical Press
• Subjects: Asthma; Care and treatment; dupilumab; exacerbation; Interleukins; Monoclonal antibodies; Original Research; real-world; severe asthma; transient eosinophilia; Japan; severe asthma; real-world; transient eosinophilia; dupilumab; exacerbation
• ISSN: 1178-6965; 1178-6965
• DOI: 10.2147/JAA.S357548

Treatment with dupilumab, an anti-interleukin (IL)-4 receptor α monoclonal antibody that blocks both the IL-4 and IL-13 pathways, has demonstrated efficacy for the treatment of severe asthma (SA) with type 2 inflammation. However, few studies have focused on the efficacy of this biologic for the treatment of SA in a real-world setting. From April 2019 to December 2021, 26 Japanese patients with SA received dupilumab at Jikei University Hospital. We retrospectively evaluated the number of moderate-to-severe exacerbations, pulmonary function, maintenance dose of corticosteroids, biomarkers, and adverse events. During a mean follow-up period of 12.6 months, 10 patients received dupilumab as the first biologic, and 16 switched to dupilumab from other biologics. Dupilumab treatment significantly reduced the number of annual exacerbations from 3.4 ± 4.1 to 1.6 ± 2.7 (/person-year, p < 0.01) at the last follow-up regardless of previous biologic use. The Asthma Control Test score significantly improved in all patients by six months after administration but tended to worsen by 24 months in patients with previous biologic use. On the other hand, blood eosinophil counts (BECs) transiently increased and peaked three to six months after administration. The peak timing can be affected by previous biologic use. Adverse events included wheezing immediately after injection, hypereosinophilia, mild conjunctivitis, and relapse of chronic eosinophilic pneumonia in the patient switched from benralizumab. Dupilumab treatment was useful for patients with SA in a real-world setting. However, the BEC should be monitored carefully, especially in patients who previously received anti-IL-5/IL-5 receptor antibody.